Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385778892> ?p ?o ?g. }
- W4385778892 endingPage "691" @default.
- W4385778892 startingPage "678" @default.
- W4385778892 abstract "Vaccine-elicited immune responses are impaired in patients with inflammatory bowel disease (IBD) treated with anti-TNF biologics.To assess vaccination efficacy against the novel omicron sublineages BQ.1.1 and XBB.1.5 in immunosuppressed patients with IBD.This prospective multicentre case-control study included 98 biologic-treated patients with IBD and 48 healthy controls. Anti-spike IgG concentrations and surrogate neutralisation against SARS-CoV-2 wild-type, BA.1, BA.5, BQ.1.1, and XBB.1.5 were measured at two different time points (2-16 weeks and 22-40 weeks) following third dose vaccination. Surrogate neutralisation was based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Primary outcome was surrogate neutralisation against tested SARS-CoV-2 sublineages. Secondary outcomes were proportions of participants with insufficient surrogate neutralisation, impact of breakthrough infection, and correlation of surrogate neutralisation with anti-spike IgG concentration.Surrogate neutralisation against all tested sublineages was reduced in patients with IBD who were treated with anti-TNF biologics compared to patients treated with non-anti-TNF biologics and healthy controls (each p ≤ 0.001) at visit 1. Anti-TNF therapy (odds ratio 0.29 [95% CI 0.19-0.46]) and time since vaccination (0.85 [0.72-1.00]) were associated with low, and mRNA-1273 vaccination (1.86 [1.12-3.08]) with high wild-type surrogate neutralisation in a β-regression model. Accordingly, higher proportions of patients treated with anti-TNF biologics had insufficient surrogate neutralisation against omicron sublineages at visit 1 compared to patients treated with non-anti-TNF biologics and healthy controls (each p ≤ 0.015). Surrogate neutralisation against all tested sublineages decreased over time but was increased by breakthrough infection. Anti-spike IgG concentrations correlated with surrogate neutralisation.Patients with IBD who are treated with anti-TNF biologics show impaired neutralisation against novel omicron sublineages BQ.1.1 and XBB.1.5 and may benefit from prioritisation for future variant-adapted vaccines." @default.
- W4385778892 created "2023-08-13" @default.
- W4385778892 creator A5001079928 @default.
- W4385778892 creator A5001322752 @default.
- W4385778892 creator A5001761071 @default.
- W4385778892 creator A5002998900 @default.
- W4385778892 creator A5008056628 @default.
- W4385778892 creator A5012813564 @default.
- W4385778892 creator A5014244441 @default.
- W4385778892 creator A5015203112 @default.
- W4385778892 creator A5022087100 @default.
- W4385778892 creator A5025026489 @default.
- W4385778892 creator A5029755492 @default.
- W4385778892 creator A5034794115 @default.
- W4385778892 creator A5036202628 @default.
- W4385778892 creator A5040267099 @default.
- W4385778892 creator A5046104068 @default.
- W4385778892 creator A5050482459 @default.
- W4385778892 creator A5054681942 @default.
- W4385778892 creator A5059806046 @default.
- W4385778892 creator A5070149012 @default.
- W4385778892 creator A5072818031 @default.
- W4385778892 creator A5073038812 @default.
- W4385778892 creator A5076893798 @default.
- W4385778892 creator A5078154052 @default.
- W4385778892 creator A5003916473 @default.
- W4385778892 creator A5004363363 @default.
- W4385778892 creator A5056387073 @default.
- W4385778892 date "2023-08-12" @default.
- W4385778892 modified "2023-10-11" @default.
- W4385778892 title "STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease" @default.
- W4385778892 cites W2198790708 @default.
- W4385778892 cites W3044482768 @default.
- W4385778892 cites W3080375150 @default.
- W4385778892 cites W3082734312 @default.
- W4385778892 cites W3094105410 @default.
- W4385778892 cites W3158750369 @default.
- W4385778892 cites W3165479483 @default.
- W4385778892 cites W3170606898 @default.
- W4385778892 cites W3187717873 @default.
- W4385778892 cites W3198593273 @default.
- W4385778892 cites W3211135479 @default.
- W4385778892 cites W4210350488 @default.
- W4385778892 cites W4212768856 @default.
- W4385778892 cites W4220673385 @default.
- W4385778892 cites W4220724000 @default.
- W4385778892 cites W4220897177 @default.
- W4385778892 cites W4221046699 @default.
- W4385778892 cites W4221088689 @default.
- W4385778892 cites W4224043752 @default.
- W4385778892 cites W4225310481 @default.
- W4385778892 cites W4225470021 @default.
- W4385778892 cites W4225691034 @default.
- W4385778892 cites W4226229183 @default.
- W4385778892 cites W4281287406 @default.
- W4385778892 cites W4281556594 @default.
- W4385778892 cites W4283122765 @default.
- W4385778892 cites W4283395367 @default.
- W4385778892 cites W4284886202 @default.
- W4385778892 cites W4286615180 @default.
- W4385778892 cites W4288443557 @default.
- W4385778892 cites W4293843074 @default.
- W4385778892 cites W4295204307 @default.
- W4385778892 cites W4296026861 @default.
- W4385778892 cites W4296330936 @default.
- W4385778892 cites W4306756792 @default.
- W4385778892 cites W4306874674 @default.
- W4385778892 cites W4307402977 @default.
- W4385778892 cites W4307584157 @default.
- W4385778892 cites W4308937751 @default.
- W4385778892 cites W4310718486 @default.
- W4385778892 cites W4310828358 @default.
- W4385778892 cites W4311288827 @default.
- W4385778892 cites W4311359167 @default.
- W4385778892 cites W4313454081 @default.
- W4385778892 cites W4313830553 @default.
- W4385778892 cites W4317358762 @default.
- W4385778892 cites W4318833625 @default.
- W4385778892 cites W4323043940 @default.
- W4385778892 cites W4328054000 @default.
- W4385778892 cites W4360999097 @default.
- W4385778892 cites W4362566841 @default.
- W4385778892 cites W4365517147 @default.
- W4385778892 cites W4366287746 @default.
- W4385778892 cites W4377115745 @default.
- W4385778892 cites W4379645565 @default.
- W4385778892 cites W4380569299 @default.
- W4385778892 cites W4381926480 @default.
- W4385778892 doi "https://doi.org/10.1111/apt.17661" @default.
- W4385778892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37571863" @default.
- W4385778892 hasPublicationYear "2023" @default.
- W4385778892 type Work @default.
- W4385778892 citedByCount "0" @default.
- W4385778892 crossrefType "journal-article" @default.
- W4385778892 hasAuthorship W4385778892A5001079928 @default.
- W4385778892 hasAuthorship W4385778892A5001322752 @default.
- W4385778892 hasAuthorship W4385778892A5001761071 @default.
- W4385778892 hasAuthorship W4385778892A5002998900 @default.